Related Experiment Video
Updated: May 5, 2026
06:53
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
Published on: June 8, 2019
9.9K
Circulating tumor DNA in lymphoma: technologies and applications
Lina Fu1,2, Xuerong Zhou3, Xiaoyu Zhang4
1Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, Anhui Province, China.
Journal of Hematology & Oncology
|March 12, 2025
Summary
Liquid biopsy using circulating tumor DNA (ctDNA) offers a non-invasive method for lymphoma diagnosis and monitoring. This approach aids in personalized treatment strategies and improves patient outcomes by detecting genetic changes and minimal residual disease.
Area of Science:
- Oncology
- Molecular Diagnostics
- Genetics
Background:
- Lymphoma diagnosis and monitoring traditionally rely on invasive biopsies and imaging, which have limitations.
- Deep-seated lymphomas and the risk of complications hinder traditional diagnostic methods.
- Current imaging lacks sensitivity for early clonal evolution and minimal residual disease (MRD).
Purpose of the Study:
- To review the role of circulating tumor DNA (ctDNA) in lymphoma management.
- To evaluate ctDNA detection technologies and their applications in various lymphoma subtypes.
- To highlight ctDNA's potential in advancing precision medicine for lymphoma.
Main Methods:
- Comprehensive review of common genetic variations in lymphoma.
- Systematic evaluation of ctDNA detection technologies (PCR, NGS).
- Discussion of ctDNA applications: noninvasive genotyping, risk stratification, treatment response, and MRD detection.
Main Results:
- ctDNA analysis provides non-invasive genetic and epigenetic insights into lymphoma.
- ctDNA serves as a dynamic biomarker for diagnosis, risk stratification, and treatment response.
- ctDNA profiling demonstrates utility across diffuse large B-cell lymphoma, Hodgkin lymphoma, follicular lymphoma, and T-cell lymphoma.
Conclusions:
- ctDNA liquid biopsy overcomes limitations of invasive procedures and spatial heterogeneity.
- ctDNA profiling enables personalized therapeutic strategies and improved clinical outcomes in lymphoma.
- ctDNA is a key biomarker for advancing precision medicine in lymphoma care.
